Fore Bio
formerly FORE BiotherapeuticsFore Biotherapeutics
Israel · Founded 2011 · $237.4M raised
- Employees
- 11–50
- Founded
- 2011
- Business Model
- B2B
- Website
- fore.bio
- Total Funding
- $237.4M
- Last Round
- $75.0M Series DJul 2026
- Rounds
- 5
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Fore Biotherapeutics is a precision oncology company developing cancer therapies guided by proprietary functional genomics. Its lead program, plixorafenib (FORE-8394), is being evaluated in the FORTE Trial for patients with BRAF-altered solid tumors. The company is committed to patient-first, hypothesis-driven science to address difficult-to-treat cancers.
Summary
Fore Bio is a Biotech company based in Israel, founded in 2011. It has raised $237.4M in total across 5 rounds, most recently a $75.0M Series D round in Jul 2026. Investors include OrbiMed, Medicxi and Novartis Venture Fund.
Funding History
Jul 2026
Sign up to see all 5 events
Funding: Series A through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/fore-bio"><img src="https://indexed.vc/api/badge/company/fore-bio" alt="Fore Bio on Indexed.vc" width="260" height="76" /></a>